| India | Branded generics prescription specialty products | Strong brand presence, first-to-market products, extensive sales network | B2B and B2C, including hospitals and pharmacies | Specialty branded generics in cardiology and dermatology | 1452 | 31 | Sales through healthcare providers, distributors, retail pharmacies | Direct sales with pricing aligned to market standards | Specialty chronic therapies adoption and market penetration | Brands in cardiology, dermatology, ophthalmology such as Montelukast and Pinkoo Gripe Water |
| Emerging Market | Branded generics in multiple therapeutic areas plus institutional sales | WHO prequalification, exclusive government contracts, geographic reach | B2B and B2G, including government healthcare institutions | Chronic disease portfolios in branded generics | 1941 | 42 | Sales via distributors and government tenders | Tender-based and long-term contracts with governments | Expansion in Africa and Asia, institutional contracts, WHO programs | Anti-Malarial, Anti-Biotic, Cardiology brands tailored for Africa, CIS and Asia |
| Africa Institution | Institutional supply of pharmaceuticals to public health programs | WHO prequalification, trusted supplier status | B2G, governments and international health organizations | Institutional sales with stable margins | 147 | 3 | Government contracts and donor-funded tenders | Contractual supply agreements | Continued government program funding and approvals | Anti-Malarial drugs supplied under WHO and government programs |
| USA | Approved ANDAs for generic pharmaceutical products | USFDA-approved manufacturing, robust ANDA pipeline | B2B, US healthcare providers, pharmacies, wholesalers | First-to-market generics in chronic therapies | 1047 | 22 | Sales to wholesalers, pharmacies under generic drug pricing | Market-based generic pricing and volume sales | Growing US approvals and product launches | Generics such as Montelukast formulations |
